ArticleBlood cell therapy2026
Dosing Subcutaneous Immunoglobulin to Achieve Target Levels in Hematopoietic Cell Transplant Recipients.
Article in Blood cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary hypogammaglobulinemia (SHG) is a frequent complication after hematopoietic cell transplantation (HCT), especially allogeneic HCT, and predisposes to recurrent or severe infections. Immunoglobulin replacement therapy (IgRT) is commonly used, but the dose-response relationship between subcutaneous IgRT (ScIgRT) and serum IgG levels after HCT remains insufficiently defined. We assessed the association between ScIgRT dose and short-term changes in IgG. We performed a single-center retrospective cohort study of patients who initiated ScIgRT ≥ 60 days after autologous or allogeneic HCT (2017-2023). Eligibility required IgG measurement within 1 week before and 1 month (±1 week) after initiation; patients who received intravenous IgRT within 1 month or had active relapse/progression were excluded. Change in IgG was compared using the Mann-Whitney U test, and dose-response was evaluated with Pearson correlation (two-sided
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.